

## International Symposium on Hodgkin Lymphoma Program at a Glance (This Version: October, 2018)

Description   Authority   Posterior   Po	Piogiaili at	a Giance (Inis version	. UCIODEI, 2010)			
(Gotally M. Heritades, A. User / Injectionary, N. Disolator)  3. Every Internation, 1. Every Commission, D. Biolator)  3. Every Commission, D. Biolator)  3. Every Commission, D. Biolator)  4. Repeated Commission, C. Biolatory  5. Every Commission, C. Biolatory  5. Every Commission, C. Biolatory  6. Repeated Commission, C. Biolatory  6	Saturday (27.10.2018)	Sunday (28.10.2018)		Monday (29.10.2018)		
**Adambergy in Salang C. Manni-Schalley, J. Wholosom) **Developing Health Care Evolution Mention Temporary (M. Deletin, M. Meignon) **Developing Health Care Evolution Mention Temporary (M. Deletin, M. Meignon) **Developing Health Care Evolution Mention Temporary (M. Deletin, M. Meignon) **Developing Health Care Evolution Mention Temporary (M. Deletin, M. Meignon) **Developing Health Care Evolution Mention Temporary (M. Deletin, M. Meignon) **Developing Health Care Evolution Mention Temporary (M. Deletin, M. Meignon) **Developing Health Care Mention Temporary (M. Deletin, M. Meignon) **Developing Health Care Mention Temporary (M. Deletin, M. Meignon) **Developing Health Care Mention Temporary (M. Deletin, M. Meignon) **Developing Health Care Mention Temporary (M. Deletin, M. Meignon) **Developing Health Care Mention Temporary (M. Deletin, M. Meignon) **Developing Health Care Mention Temporary (M. Deletin, M. Meignon) **Developing Health Care Mention Temporary (M. Deletin, M. Meignon) **Developing Health Care Mention Temporary (M. Deletin, M. Meignon) **Developing Health Care Mention Temporary (M. Deletin, M. Meignon) **Developing Health Care Mention Temporary (M. Deletin, M. Meignon) **Developing Health Care Mention Temporary (M. Deletin, M. Meignon) **Developing Health Care Mention Temporary (M. Deletin, M. Meignon) **Developing Health Care Mention Temporary (M. Deletin, M. Meignon) **Inclinated Health Care Mention Temporary (M. Deletin, M. Meignon) **Inclinated Health Care Mention Temporary (M. Deletin, M. Mention M. Mention Temporary (M. Deletin, M. Mention M. Mention M. Mention Mentio	00 / 5 - 10 / 5 W - 1   1	(Faculty: M. Hertzberg, A. Lister / Presenters: D. A. Eichenauer, J. Romejko-Jarosinska, O. Baiocchi, S. Borchmann) 1. Stage IV NLPHL (D. Eichenauer) 2. Elderly cHL (J. Romejko-Jarosinska) 3. HIV-positive HL (O. Baiocchi)		(V. Diehl, P. Johnson)  • ECHELON1 Update (J. Radford)  • HD18 Update (P. Borchmann)  • LYSA AHL2011 Phase III Study (O. Casasnovas)		07:30
**Indicate Processing (P. L. Monamon, C. Sterid) Dr. Nigophele, D. Horizo Dr. Nigophele, Dr. Nigophele, Dr. Dr. Nigophele, Dr. Dr. Nigophele, Dr. Dr. Nigophele, Dr.	•					09:00
10:30 – 12:00 Biology & Microenvironment (A. von Geb Begs, C. Seld (B. von Geb Begs))  Coffee Break  12:15 – 13:45 Biosimilar rituximab (B. R.)  12:15 – 13:45 Siosimilar rituximab (B	<ul> <li>Molecular Pathogenesis (M. I. Hansmann, C. Steidl)</li> <li>Developing Health Care Environments (A. Hagenbeek, O. Henke)</li> </ul>	09:15 – 10:15 <b>Oncology meets Autoimmunity</b> <i>by Chugai (A. Engert)</i> • Autotransplant in systemic sclerosis (J. Henes)		09:15 – 10:15 CAR T Cell Therapies: Hype Or Hope? by Celgene (H. Einsele)  • Preclinical Rationale for CAR T Cell Therapy (S. Thomas) • CD19 directed CAR T Cell Therapy in B-NHL (P. Borchmann)		09:15
A. van den Berg, C. Sleid)   A. van den Berg, C. van deen wee, A. Parto   A. van den Berg, C. van dee	Coffee Break	Coffee Break		Coffee Break		
Coffee Break  12:15 - 13:45 Biosimilar rituximab - a new treatment option by Sondoz Germany (A. Engert)  - Isolimilar Development in Oncology (T. Dingerman)  - Clinical evidence for biosimilar nutumab (b. N.)  - Treatment of CD2 positive, lymphocyte-predominant biologistic lymphomas (b. Exhibition)  - Considering consolidation is attributed for (B. Borchmann)  - Confee Break  12:15 - 13:45 H.: Tailoring sequencing and treatment of CD2 positive, lymphomas (D. Rod))  - Velocima and introduction (B. Borchmann)  - Confeeing consolidation is attributed to the standard of CD2 positive, lymphomas (D. Rod))  - Confeeing consolidation is attributed treatment of CD2 positive, lymphomas (D. Rod))  - Pol-1 biologistic quirrent and future aspects of clit therapy (B. Borchmann)  - Pol-1 biologistic quirrent and future aspects of clit therapy (B. Borchmann)  - Pol-1 biologistic quirrent and future aspects of clit therapy (B. Borchmann)  - Pol-1 biologistic properties (C. Borchmann)  - Pol-1 biologistic in NHIs (R. L. Zimzeni)  - Pol-1 biologistic in NHIs	Survivorship (F. van Leeuwen, A. Plate)     Immunotherapy: Chances & Pitfalls (P. Armand, T. Illidge)     Challenges in Older Lymphoma Patients (P. Brice, J. Friedberg)	(A. van den Berg, C. Steidl)  - Microenvironment (R. Küppers)  - Genotyping of cHL via Liquid Biopsy (D. Rossi)		(C. Mauz-Körholz, K. M. Kelly)  • PD1/-L1 Expression in Pediatric HL (S. Gattenlöhner)  • Genotyping in Familial HL (J. Yang)  • Functional and Financial Outcomes after Treatment for Pediatric Hodgkin Lymphoma (S. Parsons)		10:30
12:15 – 13:45 Biosimilar rituximab – a new treatment option by Sondoz Germony (A. Engert) - Biosimilar Devolute (P. Boptmann) - Unicial service for biosimilar rituximab (N. M.) - Teratment of 120 positive, lympodyce-perdominant lodgisin lymphoma (D. Eichenauer) - Considering consolidation after autologous stem cell transplantation (D. Molin) - Relapse after autologous transplant options and optimising outcomes (K. Suredo) - Considering patient factors: challenging cases and clinical management (M. Facilitated by P. Bachmann) - Po-1 blockade in NHs (P. I. Zinzani) - Po-1 blockade in NHs (P. I. Zin		Ural Abstract Presentations		oldi Abstract Presentations		12:00
14:00 – 15:30 Immunotherapy – Biomechanisms (A. Rosenwold, M. Shipp)  -T-cells and PD1 Inhibition in cH. (M. Shipp)  -Immune-Evasion (M. K. Gandhi)  Oral Abstract Presentations  15:00 – 17:30 Advanced Ht. How Can We Do Better? by Takeda / Medscape (M. Hertzberg)  - Introduction (M. Hertzberg)  - Introduction (M. Hertzberg)  - Introduction (M. Hertzberg)  - Introduction (M. Hertzberg)  - Indeed discussion (below: Q&A) (A. Povlovsky)  - Assessing risk of failure throughout treatment (Q&A) (A. Moskowitz)  - Assessing risk of failure throughout treatment (Q&A) (A. Moskowitz)  - Assessing risk of failure throughout treatment (Q&A) (A. Moskowitz)  - Tive Solvage (Q&A) (A. Moskowitz)  - Novel Agents in First Line Salvage (R. Advani)  Oral Abstract Presentations  17:45 – 19:15 Survivorship & Patients' Perspective (R. Vancovick)  - Orginitive Behavioral Therapy for Fatigue in Ht. (H. Knoop)  - Genetic Susceptibility (L. Morton)  Oral Abstract Presentations	12:15 – 13:45 <b>Biosimilar rituximab – a new treatment option</b> by Sandoz Germany (A. Engert)  Biosimilar Development in Oncology (T. Dingermann)  Clinical evidence for biosimilar rituximab (N. N.)  Treatment of CD20 positive, lymphocyte-predominant	12:15 – 13:45 HL: Tailoring sequencing and treatment targets. by Takeda (P. Borchmann)  • Welcome and introduction (P. Borchmann)  • Considering consolidation after autologous stem cell transplantation (D. Molin)  • Relapse after autologous transplant: options and optimising outcomes (A. Sureda)  • Considering patient factors: challenging cases and clinical		12:15 – 13:45 <b>Checkpointblockade in Lymphomas</b> <i>by MSD (A. Engert)</i> Basics in immunotherapy for lymphomas ( <i>D. Wolf</i> )  PD-1 blockade current and future aspects of cHL therapy ( <i>P. Borchmann</i> )		12:15
(A. Rosenwold, M. Shipp)  -T-cells and PD1 Inhibition in cHL (M. Shipp) -Immune-Evasion (M. K. Gandhi)  Oral Abstract Presentations  15:00-17:30 Advanced HL: How Can We Do Better? by Takedo /Medscape (M. Hertzberg)  Introduction (M. Hertzberg)  Int	Coffee Break	Coffee Break		Coffee Break		
Coffee Break  Coffee Break  Coffee Break  Poster Session  Coffee Break  16:00 – 17:30 Focus on cHL: Current Insights and Future Perspectives by Bristol-Myers Squibb (P. Borchmann)  - Can we do better in front-line? followed by iPad Audience Q&A with panel discussion (below: Q&A) (R. Pavlovsky)  - Can we do better with salvage? (Q&A) (R. Pavlovsky)  - Sasessing risk of failure throughout treatment (Q&A) (M. Hutchings)  - Conclusion (M. Hertzberg)  Coffee Break  Coffee Break  Coffee Break  Coffee Break  Coffee Break  77:45  Opening Ceremony  Coffee Break  Coffee Break  Coffee Break  17:45 - 19:15 Survivorship & Patients' Perspective (F. van Leeuwen, A. Plate)  - What Patients Really Want: The Global lymphoma Patient Survey (I. Warwick)  - Ognitive Behavioral Therapy for Fatigue in HL (H. Knoop)  - Genetic Susceptibility (I. Morton)  Oral Abstract Presentations	(A. Rosenwald, M. Shipp)  - T-cells and PD1 Inhibition in cHL (M. Shipp)	(R. Hoppe, J. Raemaekers)  - Early-Stage Favorable HL: HD16 (A. Engert)		(P. Armand, M. Hutchings)  Checkmate 205: Cohort D (S. Ansell)  Toxicities from Checkpoint Inhibitor Therapy: Diagnosis,		14:00
16:00 – 17:30 Advanced HL: How Can We Do Better? by Takeda / Medscape (M. Hertzberg)  - Introduction (M. Hertzberg)  - Can we do better in front-line? followed by iPad Audience Q&A with panel discussion (below: Q&A) (A. Pavlovsky)  - Can we do better with salvage? (Q&A) (A. Pavlovsky)  - Assessing risk of failure throughout treatment (Q&A)  (M. Hutchings)  - Conclusion (M. Hertzberg)  - Panel Discussion  17:45  Opening Ceremony  16:00 – 17:30 Relapsed/Refractory HL (C. H. Moskowitz, A. Sureda)  - BRAVE: Phase II Trial (A. Hagenbeek)  - Novel Agents in First Line Salvage (R. Advani)  - Focus on Element (M. Shipp)  - Panel Discussion  17:45  Oral Abstract Presentations  17:30 – 18:15  Closing Remarks  17:30 – 18:15  Closing Remarks  17:30 – 18:15  Closing Remarks	Oral Abstract Presentations	Oral Abstract Presentations		Oral Abstract Presentations		15:30
Better? by Takeda /Medscape (M. Hertzberg)  Introduction (M. Hertzberg)  I	Coffee Break	Coffee Break	Poster Session	Coffee Break	Poster Session	
17:45 17:45 17:45 17:45 17:45 Survivorship & Patients' Perspective (F. van Leeuwen, A. Plate)  • What Patients Really Want: The Global Lymphoma Patient Survey (L. Warwick)  • Cognitive Behavioral Therapy for Fatigue in HL (H. Knoop)  • Genetic Susceptibility (L. Morton)  Oral Abstract Presentations	Better? by Takeda / Medscape (M. Hertzberg)  Introduction (M. Hertzberg)  Can we do better in front-line? followed by iPad Audience (\(\text{Q&A}\) with panel discussion (below: (\(\text{Q&A}\)) (A. Pavlovsky)  Can we do better with salvage? ((\(\text{Q&A}\)) (C. H. Moskowitz)  Assessing risk of failure throughout treatment ((\(\text{Q&A}\)) (M. Hutchings)	Future Perspectives by Br (P. Borchmann)  The Evolving cHL Treatment La  Understanding the Unmet Nee Focus on Biomarkers: Biology Benefit (M. Shipp)	istol-Myers Squibb ndscape (G. Collins) ed in cHL (P. Borchmann)	(C. H. Moskowitz, A. Sureda)  BRaVE: Phase II Trial (A. Hagenbeek)  Novel Agents in First Line Salvage (R. Advani)		16:00 17:30
Opening Ceremony  (F. van Leeuwen, A. Plate)  - What Patients Really Want: The Global Lymphoma Patient Survey (L. Warwick)  - Cognitive Behavioral Therapy for Fatigue in HL (H. Knoop)  - Genetic Susceptibility (L. Morton)  Oral Abstract Presentations	Coffee Break	Coffee Break				
		<ul> <li>(F. van Leeuwen, A. Plate)</li> <li>What Patients Really Want: The Global lymphoma Patient Survey (L. Warwick)</li> <li>Cognitive Behavioral Therapy for Fatigue in HL (H. Knoop)</li> <li>Genetic Susceptibility (L. Morton)</li> </ul>		Closing Remarks		17:45
<u> </u>						19:15

19:45 Welcome Reception

19:45